Should I buy or sell Oxford Biomedica stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares. View OXB analyst ratings or view top-rated stocks .

What is Oxford Biomedica's stock price target for 2024?

3 brokerages have issued 12-month price targets for Oxford Biomedica's shares. Their OXB share price targets range from GBX 310 to GBX 1,010. On average, they anticipate the company's share price to reach GBX 605 in the next year. This suggests a possible upside of 250.5% from the stock's current price. View analysts price targets for OXB or view top-rated stocks among Wall Street analysts .

How have OXB shares performed in 2023?

Oxford Biomedica's stock was trading at GBX 442.50 at the start of the year. Since then, OXB stock has decreased by 61.0% and is now trading at GBX 172.60. View the best growth stocks for 2023 here .

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ) , Petra Diamonds (PDL) , Sirius Minerals (SXX) , Centamin (CEY) , Lloyds Banking Group (LLOY) , Oxford Biomedica (OXBDF) , Premier Oil (PMO) , AFR.L (AFR) , Barclays (BARC) and Genel Energy (GENL) .

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

Oxford Biomedica Share Price, News & Analysis (LON:OXB)

GBX 172.60

+0.60 (+0.35%)

(As of 04:45 PM ET)

Compare

Today's Range: 171
▼
175.21
50-Day Range: 171.80
▼
307.50
52-Week Range: 171
▼
575

Volume: 233,564 shs
Average Volume: 154,376 shs
Market Capitalization: £167.04 million

P/E Ratio: N/A
Dividend Yield: 4.57%
Price Target: GBX 605

Stock Analysis Analyst Forecasts Chart Competitors Headlines Insider Trades

Oxford Biomedica MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 250.5% Upside
GBX 605 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
£12.12 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
Oxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 605, Oxford Biomedica has a forecasted upside of 250.5% from its current price of GBX 172.60.
Amount of Analyst Coverage
Oxford Biomedica has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for OXB.

1.7

Dividend Strength

Dividend Leadership
Oxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Oxford Biomedica does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OXB.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oxford Biomedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought £121,206.20 in company stock and sold GBX 0 in company stock.
Percentage Held by Insiders
Only 8.68% of the stock of Oxford Biomedica is held by insiders.
Percentage Held by Institutions
67.05% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oxford Biomedica is -269.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oxford Biomedica is -269.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oxford Biomedica has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oxford Biomedica Stock (LON:OXB)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OXB Stock News Headlines

October 22, 2023 | finance.yahoo.com

Oxford Biomedica's UK£39m Market Cap Fall Books Insider Losses

September 22, 2023 | finance.yahoo.com

Oxford Biomedica First Half 2023 Earnings: Misses Expectations

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

September 20, 2023 | finance.yahoo.com

Oxford BioMedica shares soar as vaccine maker raises earnings guidance

July 18, 2023 | finance.yahoo.com

Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook

May 25, 2023 | msn.com

RBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform Recommendation

May 15, 2023 | finance.yahoo.com

Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system

May 5, 2023 | finance.yahoo.com

Why Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/S

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

April 26, 2023 | finance.yahoo.com

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

April 25, 2023 | markets.businessinsider.com

Oxford Biomedica Posts FY Loss

April 21, 2023 | marketwatch.com

2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and Forecast

April 12, 2023 | marketwatch.com

2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern Trend

March 26, 2023 | marketwatch.com

CGT CDMO Market Share and Forecast till 2030

March 15, 2023 | benzinga.com

Oxford BioMedica Stock (OTC:OXBDF), Quotes and News Summary

March 11, 2023 | finance.yahoo.com

As Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this year

February 25, 2023 | marketwatch.com

What is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key Players

February 22, 2023 | marketwatch.com

CGT CDMO Market Size Global Research Report, 2023 - 2028

January 30, 2023 | marketwatch.com

CGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028

January 20, 2023 | marketwatch.com

CGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028

January 12, 2023 | marketwatch.com

CGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 Insights

January 1, 2023 | finance.yahoo.com

A Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)

December 14, 2022 | yahoo.com

Oxford Biomedica Solutions forms new partnerships with three biotechnology companies

December 9, 2022 | marketwatch.com

CGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028

November 22, 2022 | finance.yahoo.com

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

October 25, 2022 | marketwatch.com

CGT CDMO Market Size 2022 Is Changing Consumer Habits, this Industry in the Globe Has Noticed Substantial Growth to 2028 | 112 Pages Report

October 7, 2022 | finance.yahoo.com

Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree

See More Headlines

Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:OXB
CUSIP: N/A
CIK: N/A
Web: www.oxfordbiomedica.co.uk
Phone: +44-1865-783000
Fax: N/A
Employees: 891
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: GBX 605
High Stock Price Target: GBX 1,010
Low Stock Price Target: GBX 310
Potential Upside/Downside: +250.9%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX (0.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-61,630,000.00
Net Margins: -51.78%
Pretax Margin: N/A
Return on Equity: -30.64%
Return on Assets: -12.05%

Debt

Debt-to-Equity Ratio: 57.10
Current Ratio: 3.32
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: £119.02 million
Price / Sales: 1.40
Cash Flow: GBX 57.34 per share
Price / Cash Flow: 3.01
Book Value: GBX 178 per share
Price / Book: 0.97

Miscellaneous

Outstanding Shares: 96,780,000
Free Float: N/A
Market Cap: £166.85 million
Optionable: Not Optionable
Beta: 1.02

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Stuart Paynter (Age 50)
CFO, Company Secretary & Director
Comp: $832k
Dr. Frank Mathias (Age 61)
CEO & Director
Mr. Thierry Cournez
COO & Site Head of UK Operations
Dr. James Miskin Ph.D.
Chief Technical Officer
Dr. Kyriacos Mitrophanous Ph.D.
Chief Scientific Officer
Mr. Matthew Treagus
Chief Information Officer & Chief of Staff
Sophia Bolhassan
Head of Investor Relations
Ms. Natalie Louise Walter
General Counsel
Ms. Lisa James
Chief People Officer
Ms. Kati Hudson
Head of Intellectual Property and Contracts

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

OXB Stock Analysis - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.
View OXB analyst ratings or view top-rated stocks.
What is Oxford Biomedica's stock price target for 2024?: 3 brokerages have issued 12-month price targets for Oxford Biomedica's shares. Their OXB share price targets range from GBX 310 to GBX 1,010. On average, they anticipate the company's share price to reach GBX 605 in the next year. This suggests a possible upside of 250.5% from the stock's current price.
View analysts price targets for OXB or view top-rated stocks among Wall Street analysts.
How have OXB shares performed in 2023?: Oxford Biomedica's stock was trading at GBX 442.50 at the start of the year. Since then, OXB stock has decreased by 61.0% and is now trading at GBX 172.60.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Oxford Biomedica own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).
How do I buy shares of Oxford Biomedica?: Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:OXB) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oxford Biomedica Share Price, News & Analysis (LON:OXB)

Oxford Biomedica MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Oxford Biomedica Stock (LON:OXB)

OXB Stock Price History

OXB Stock News Headlines

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

OXB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™